UNSPSC 51384627: Metamizole sodium

This classification denotes an anti-inflammatory agents, non-steroidal, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VSU62Z74ON. European Medicines Agency schedules Metamizole sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08810MIG. Metamizole sodium generally arises in the molecular formula C13H16N3O4S.NA. The term METAMIZOLE SODIUM is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule metamizole sodium under HS 29331190.

As of Q4 2014, METAMIZOLE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: CC1C(C(=O)N(N1C)C2CCCCC2)N(C)CS(=O)(=O)[O-].[NA+].

UNSPSC 51384627 Metamizole sodium is a Commodity code that captures state and local procurement of pharmaceutical products, though recent solicitations under this code show limited direct alignment with metamizole sodium itself. Instead, state and local buyers are using this taxonomy code to procure broader pharmaceutical categories including naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. State health agencies, county public health departments, and cooperative purchasing alliances serve as the primary issuing bodies. The work involves sourcing finished pharmaceutical products for distribution through established wholesaler networks or direct to end-use facilities, with vendors required to comply with FDA manufacturing standards, Drug Supply Chain Security Act (DSCSA) certification, good manufacturing practices (cGMP), insurance requirements, and federal workplace and eligibility verification mandates.

Recent activity spans Florida, Texas, and Minnesota through distinct procurement mechanisms. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, responses due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, signaling exploratory procurement interest before formal RFP issuance. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. MMCAP's RFP emphasizes pricing competitiveness (75 percent evaluation weight), EDI capability, compliance with pharmaceutical data format requirements, and mandatory use of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, Morris & Dickson Co., LLC).